Information Provided By:
Fly News Breaks for May 27, 2016
RHHBY, BIIB
May 27, 2016 | 14:45 EDT
Leerink analyst Geoffrey Porges noted that Biogen (BIIB) has a profit sharing agreement with Roche (RHHBY) for Rituxan and Gazyva and called the top-line PFS data reported from Roche's Phase 3 GALLIUM study comparing Gazyva with Rituxan in certain lymphoma patients an incremental positive. The preliminary study results suggest that Gazyva will rapidly become preferred over Rituxan in these indications, Porges tells investors.
News For BIIB;RHHBY From the Last 2 Days
BIIB
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
BIIB
BIIB
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BIIB
BIIB
RHHBY
RHHBY
Apr 24, 2024 | 06:30 EDT
BIIB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.